Prospective study of fluconazole therapy in systemic neonatal fungal infection.

BACKGROUND Standard neonatal systemic antifungal therapy with amphotericin B and flucytosine can be associated with toxicity, drug resistance and the need for prolonged venous access. There is consequently a need for alternative treatment options. OBJECTIVES To assess the efficacy and safety of fluconazole in the treatment of systemic neonatal fungal infections. METHOD Open, nonrandomized evaluation of fluconazole treatment in 20 consecutively enrolled neonates with systemic fungal infection. RESULTS Clinical and microbiologic cure was achieved in 12 of 19 (63%) of infants treated. One additional infant received prior amphotericin B therapy and is included for assessment of side effects. One infant with Torulopsis glabrata infection failed treatment. Six infants died of Gram-negative bacterial infection and other intercurrent medical problems. CONCLUSION Fluconazole appeared to be safe and effective for treatment of systemic candidal infection in the neonate although more data are required in very low birth weight infants.

[1]  P. Cooper,et al.  Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. , 1996, The Pediatric infectious disease journal.

[2]  K. Hoppu,et al.  Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life , 1993, Clinical pharmacology and therapeutics.

[3]  S. Wainer,et al.  Attitudes of mothers, doctors, and nurses toward neonatal intensive care in a developing society. , 1993, Pediatrics.

[4]  J. Ker,et al.  Fatal theophylline overdose. , 1993, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[5]  T. Walsh,et al.  Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. , 1992, The Journal of pediatrics.

[6]  J. Baley.  Neonatal candidiasis: the current challenge. , 1991, Clinics in perinatology.

[7]  C. Viscoli,et al.  Fluconazole in the treatment of candidiasis in immunocompromised children , 1991, Antimicrobial Agents and Chemotherapy.

[8]  G. Dettori,et al.  In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. , 1991, Chemotherapy.

[9]  S. Clissold,et al.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. , 1990, Drugs.

[10]  H. Versmold,et al.  Stroke Volume and Left Ventricular Output in Preterm Infants with Patent Ductus Arteriosus , 1990, Pediatric Research.

[11]  E. Johnson,et al.  FLUCONAZOLE RESISTANCE IN CANDIDA GLABRATA , 1988, The Lancet.

[12]  R. Faix.  Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement. , 1984, The Journal of pediatrics.

[13]  P. Ferrieri,et al.  Systemic Candidiasis in Very Low-Birth-Weight Infants (<1,500 Grams) , 1984, Pediatrics.

[14]  G. Medoff,et al.  Strategies in the treatment of systemic fungal infections. , 1980, The New England journal of medicine.